Amgen’s weight management candidate, MariTide, shows promise in the anti-obesity market. With a mean weight loss of up to 20% over 52 weeks, the drug could generate sales of $3.7 billion by 2030. Despite upcoming patent cliffs, Amgen’s deep pipeline, including bemarituzumab for cancer, supports its long-term growth prospects.

Although Amgen faces challenges like patent losses, its recent launches, like Imdelltra for lung cancer, and promising candidates like MariTide, position it for top-line growth. The company’s solid financials allow for an excellent dividend program with a 3.5% yield and room for further growth. Amgen’s forward P/E ratio of 12.6 is favorable compared to the industry average.

Investing in Amgen offers stability and potential growth, despite short-term challenges. With a strong dividend track record, deep pipeline, and attractive valuation, Amgen remains a solid choice for long-term investors. The company’s focus on innovation and strategic investments in new products should drive future success.

Read more at Yahoo Finance: 4 Reasons to Buy Amgen Stock Right Now